Abiomed, Inc.

Abiomed Announces Impella 2.5 Capacity Expansion Plans in Ireland

Published in Cardiovascular Business Week, August 19th, 2008

Abiomed, Inc. (NASDAQ: ABMD) announced that it had recently signed a long-term operating lease for a manufacturing facility in Athlone, Ireland. Abiomed expects to begin facility preparations immediately and currently anticipates that the first Impella 2.5 Cardiac Assist Device production line will be operational in approximately eighteen months.

Abiomed's Impella 2.5 capacity expansion plans in Ireland are intended to meet anticipated long-term demand for the device and augment capacity from the Company's Aachen, Germany facility. In June 2008, Abiomed announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Impella 2.5 that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2008-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry